HMI-115

DRUG3 trials

Sponsors

Hope Medicine (Nanjing) Co., Ltd

Conditions

Androgenetic AlopeciaEndometriosis

Phase 1

To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period

CompletedNCT05324293

Hope Medicine (Nanjing) Co., LtdAndrogenetic Alopecia

Start: 2022-05-11End: 2023-09-11Updated: 2024-09-19

Phase 2

A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain

CompletedNCT05101317

Hope Medicine (Nanjing) Co., LtdEndometriosis

Start: 2021-10-11End: 2025-03-19Updated: 2026-01-21

Phase 3

Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain

RecruitingNCT07318688

Hope Medicine (Nanjing) Co., LtdEndometriosis

Start: 2026-01-29End: 2028-09-01Target: 540Updated: 2026-08-11